BostonGene Corporation
June 23, 2026
Theater 1
Type: Company Presentation
Focus Area:
AI and Digital Health
BostonGene developed the first omnimodal foundation model for tumor and immune biology, redefining how oncology drugs are discovered, developed, and delivered to patients. Built and validated through years of extensive real-world clinical testing, the BostonGene platform integrates genomic, transcriptomic, immune, spatial, and clinical outcome data into a unified AI foundation that models tumor and immune biology at scale.
This biologically grounded intelligence enables biopharma partners to identify novel targets, design and de-risk clinical trials, identify novel targets and drivers, and predict therapeutic response across the development lifecycle—while simultaneously advancing precision care through clinically integrated innovation.
Company HQ City:
Waltham
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2015
Lead Product in Development:
An AI-powered, omnimodal analysis platform that integrates genomic, transcriptomic, immune, and clinical data, the BostonGene foundation model generates actionable insights for oncology drug development and patient care.
CEO
Andrew Feinberg
Development Phase of Lead Product
Multiple Products in Market
When you expect your next catalyst update?
N/A
What is your next catalyst (value inflection) update?
N/A
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}